Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Cyclin I promotes cisplatin resistance via Cdk5 activation in cervical cancer.

Li R, Liu GZ, Luo SY, Chen R, Zhang JX.

Eur Rev Med Pharmacol Sci. 2015 Dec;19(23):4533-41.

2.

The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo.

Jung HS, Erkin OC, Kwon MJ, Kim SH, Jung JI, Oh YK, Her SW, Ju W, Choi YL, Song SY, Kim JK, Kim YD, Shim GY, Shin YK.

Int J Cancer. 2012 Apr 15;130(8):1925-36. doi: 10.1002/ijc.26197. Epub 2011 Aug 8.

3.

Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.

Ma X, Zhang J, Liu S, Huang Y, Chen B, Wang D.

Cancer Chemother Pharmacol. 2012 Feb;69(2):485-94. doi: 10.1007/s00280-011-1722-9. Epub 2011 Aug 13.

PMID:
21842204
4.

MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.

Chen Y, Ke G, Han D, Liang S, Yang G, Wu X.

Exp Cell Res. 2014 Jan 1;320(1):12-20. doi: 10.1016/j.yexcr.2013.10.014. Epub 2013 Oct 31.

PMID:
24183997
5.

Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line.

Biliran H Jr, Wang Y, Banerjee S, Xu H, Heng H, Thakur A, Bollig A, Sarkar FH, Liao JD.

Clin Cancer Res. 2005 Aug 15;11(16):6075-86.

6.

Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.

Li C, Ding H, Tian J, Wu L, Wang Y, Xing Y, Chen M.

Cell Physiol Biochem. 2016;39(1):242-52. doi: 10.1159/000445620. Epub 2016 Jun 24.

8.

NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells.

Tao T, Yang X, Qin Q, Shi W, Wang Q, Yang Y, He J.

Int J Mol Sci. 2017 Jan 12;18(1). pii: E5. doi: 10.3390/ijms18010005.

9.

Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.

Cai L, Wang Z, Liu D.

Tumour Biol. 2016 May;37(5):6359-69. doi: 10.1007/s13277-015-4416-9. Epub 2015 Dec 2.

PMID:
26631032
10.

[In vitro gene silencing by siRNA of cyclin D1 on tongue squamous cell carcinoma cell line resistant to cisplatin].

Zhou XJ, Zhang ZY, Zhang P, Pan HY, Chen WT, Ye DX.

Zhonghua Kou Qiang Yi Xue Za Zhi. 2006 Nov;41(11):646-9. Chinese.

PMID:
17331354
11.

Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.

Uzawa K, Kasamatsu A, Baba T, Usukura K, Saito Y, Sakuma K, Iyoda M, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H.

Cancer Med. 2013 Feb;2(1):40-9. doi: 10.1002/cam4.56. Epub 2013 Feb 3.

12.

Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance.

Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehde U, Osmak M, Kaina B.

Int J Cancer. 2004 Dec 20;112(6):974-85.

13.
14.

Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia.

Shimanishi M, Ogi K, Sogabe Y, Kaneko T, Dehari H, Miyazaki A, Hiratsuka H.

J Oral Pathol Med. 2013 May;42(5):382-8. doi: 10.1111/jop.12028. Epub 2012 Dec 10.

PMID:
23227892
15.

Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer.

Wen Q, Liu Y, Lyu H, Xu X, Wu Q, Liu N, Yin Q, Li J, Sheng X.

Int J Gynecol Cancer. 2017 Jul;27(6):1096-1108. doi: 10.1097/IGC.0000000000001028.

16.

Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models.

Sobral LM, Sousa LO, Coletta RD, Cabral H, Greene LJ, Tajara EH, Gutkind JS, Curti C, Leopoldino AM.

Mol Cancer. 2014 Feb 20;13:32. doi: 10.1186/1476-4598-13-32.

17.

The telomere/telomerase binding factor PinX1 regulates paclitaxel sensitivity depending on spindle assembly checkpoint in human cervical squamous cell carcinomas.

Tian XP, Qian D, He LR, Huang H, Mai SJ, Li CP, Huang XX, Cai MY, Liao YJ, Kung HF, Zeng YX, Xie D.

Cancer Lett. 2014 Oct 10;353(1):104-14. doi: 10.1016/j.canlet.2014.07.012. Epub 2014 Jul 18.

PMID:
25045845
18.

Regulation of p53 expression and apoptosis by vault RNA2-1-5p in cervical cancer cells.

Kong L, Hao Q, Wang Y, Zhou P, Zou B, Zhang YX.

Oncotarget. 2015 Sep 29;6(29):28371-88. doi: 10.18632/oncotarget.4948.

19.

[Adenovirus-delivered tissue inhibitor of metalloproteinases-3 transfection increases the sensitivity of cervical cancer cells to cisplatin].

Zhang Y, Lin C, Qian HL, Lang JH, Fu M, Zhang XY, Liang X, Duan H, Xiang Y.

Zhonghua Zhong Liu Za Zhi. 2007 Jan;29(1):25-9. Chinese.

PMID:
17575689
20.

MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer.

Li J, Ping Z, Ning H.

Int J Mol Sci. 2012 Nov 28;13(12):16053-64. doi: 10.3390/ijms131216053.

Supplemental Content

Support Center